There are multiple credible accounts of reinfectionwith Covid, some as little as 2 months after first infection.

I’m excited for the success of the Pfizer vaccine as I’m not a fan of pandemics and I know that the entire world mAb manufacturing capacity is insufficient, even if diverted solely to leronlimab, to treat tens of millions of sick patients.

Plenty of room for leronlimab in Covid. The markets just don’t see it yet.